Physician profile
Lillian Howard
NPI 1992782932
$2,906.59
in general payments reported to CMS, 2019-2025
29 companies · $673 in 2025
The $673 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $92.95 · 2021: $11.89 · 2022: $182 · 2023: $622 · 2024: $1,037 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,331.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $445.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $388.89 | 2019-2025 | Evenity, Repatha, Prolia |
| Lilly USA, LLC | $355.22 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $234.90 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Edwards Lifesciences Corporation | $145.14 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $143.04 | 2023-2024 | Jot Dx, Freestyle Libre 3, Afinion 2 |
| Pfizer INC. | $140.97 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.80 | 2023-2025 | |
| Glaxosmithkline, LLC. | $107.53 | 2019-2025 | Shingrix, Arexvy |
| Exact Sciences Corporation | $90.06 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $76.78 | 2023-2025 | Rexulti |
| Sanofi Pasteur INC. | $74.32 | 2023 | |
| Dynavax Technologies Corporation | $65.14 | 2020-2025 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.36 | 2024-2025 | Jardiance |
| Shield Therapeutics INC | $49.30 | 2023-2024 | Accrufer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $48.78 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $48.19 | 2025 | |
| Dexcom, INC. | $39.00 | 2023-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $38.28 | 2024-2025 | Veozah |
| Shire North American Group INC | $37.47 | 2019 | |
| Merck Sharp & Dohme LLC | $32.01 | 2022-2025 | Gardasil 9, Capvaxive |
| Esperion Therapeutics, INC. | $31.52 | 2023-2025 | Nexletol |
| Averitas Pharma INC. | $25.83 | 2025 | Qutenza |
| Amarin Pharma, INC. | $23.03 | 2019 | |
| Allergan, INC. | $21.57 | 2020 | |
| Paratek Pharmaceuticals, INC. | $17.99 | 2025 | Nuzyra |
| Ibsa Pharma INC. | $14.01 | 2025 | Tirosint, Licart, Flector |
| Currax Pharmaceuticals LLC | $12.83 | 2023 | Contrave |
| Genentech USA, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lillian Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.